Summary Cardiac function was evaluated in 86 breast cancer patients after standard chemotherapy, followed by ablative chemotherapy and chest irradiation. One patient died of subacute heart failure 3 months after ablative chemotherapy. At a minimum of 1 year's follow-up (range 1-11 years) left vertricular ejection fraction (LVEF) was marginally abnormal in 4 of 27 disease-free survivors. One exceptional patient who received two transplantations is alive, with serious heart failure occurring after the second ablative chemotherapy. Including this patient, the percentage of patients free of clinical and subclinical cardiac dysfunction at 7 years is 78% (95% Cl 61-95%). After ablative chemotherapy, cardiotoxicity was rarely life-threatening. The impact of subclinical cardiotoxicity in the long term is not clear and needs continued evaluation.
Intensive chemotherapy, which we have defined by induction chemotherapy followed by ablative chemotherapy with bone marrow or stem cell rescue, combined with radiotherapy is, at present, a usual treatment for patients with locally advanced or disseminated breast cancer (Triozzi et al, 1995) . Many chemotherapeutic drugs and radiotherapy have toxic effects on the heart. The anthracyclines are notorious for their cumulative cardiotoxicity (Von Hoff et al, 1979; Cornbleet et al, 1984; Nielsen et al, 1990) . Late cardiotoxicity can occur more than 1 year after drug exposure (Rhoden et al, 1993; Steinherz et al, 1995) . Subacute cardiotoxicity is considered to be reversible, whereas late effects are considered to be lasting and progressive with time (Cohen et al, 1982; Saini et al, 1987; Shapiro and Henderson, 1994) . Radiationinduced heart disease (RIHD) includes late congestive heart failure (CHF) or coronary artery disease (Totterman et al, 1983; Cuzick et al, 1994; Gyenes et al, 1994; Stewart et al, 1995) . The risk of RIHD is related to the total radiation dose and the irradiated volume (Steinherz and Yahalom, 1993; Gyenes et al, 1994) . There are reports that left-sided chest irradiation causes more cardiotoxicity than right-sided irradiation (Rutqvist et al, 1992) .
Data about late cardiotoxic effects of intensive chemotherapy, combined with radiotherapy in the treatment of breast cancer, are limited. Therefore, we have evaluated the cardiac function in breast cancer patients several years after standard-dose doxorubicin-or epirubicin-based induction therapy, followed by cyclophosphamide-or mitoxantrone-based ablative therapy and irradiation. Cardiac function was evaluated by measuring left ventricular ejection fraction (LVEF) by means of a radionuclide angiography, because it is still considered to be the standard
PATIENTS AND METHODS
Eighty-six premenopausal patients with locally advanced or disseminated breast cancer were treated with intensive (induction and ablative) chemotherapy supported by bone marrow or stem cell rescue and radiotherapy between 1984 and 1994. Before treatment, none of the patients had manifest signs or symptoms of cardiac disease. Fifty-two patients (60%) were alive at the start of a cardiac evaluation in September 1994. Cardiac function was assessed in 27 of these 52 patients, who were more than 1 year in follow-up after completing intensive chemotherapy. The median follow-up of the study group was 2 years (range 1-11 years); their median age was 42 years (range 28-54 years).
The chemotherapy consisted of doxorubicin-or epirubicin-based standard induction chemotherapy, followed by cyclophosphamideor mitoxantrone-based ablative chemotherapy. Twenty-four patients received a cumulative dose of doxorubicin of 300 mg m-2 intravenously (De Graaf et al, 1994) . Three patients received a cumulative dose of epirubicin of 480 mg m-2. Six patients received a cyclophosphamide-based ablative regimen with a cumulative dose of 7 g m-2 cyclophosphamide given intravenously over three consecutive days in combination with 1.5 g m-2 etoposide (CE). Twenty patients received a mitoxantrone-based ablative regimen: in 14 patients, 50 mg m-2 mitoxantrone was combined with 800 mg m-2 thiotepa (MT); in three patients, 60 mg m-2 mitoxantrone was combined with 180 mg m-2 melphalan (MM); and in three patients, 800 mg m-2 thiotepa (TMM) was added. One patient had both CE and the TMM regimen.
Seventeen of 20 patients with locally advanced disease received 50-66 Gy locoregional radiotherapy a median of 11 weeks (range 8-19) after the ablative chemotherapy. In four of these 17 patients, this was part of a breast-conserving treatment. Of seven patients with disseminated disease, six received radiotherapy -four as primary treatment before chemotherapy and two patients after the 
RESULTS
Of the 86 patients who were treated with intensiv and irradiation for breast cancer, 34 had died befor cardiac evaluation in September 1994, leaving 52
In one of these patients, the cause of death was subacute cardiotoxicity 3 months after the ablative chemotherapy. This concerned a 42-year-old patient treated with cumulative 300 mg m-2 doxorubicin and 50 mg m-2 mitoxantrone without radiotherapy, who was admitted to the hospital because of rapidly progressive CHF. The echocardiogram showed a markedly decreased contractility, without pericardial effusion. She had no pre-existing heart disease. Post-mortem examination was denied.
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chest irradiation. All ablative regimens were based on cyclophosphamide (CE) or mitoxantrone (MT, MM or TMM) . Cyclophosphamide can induce acute cardiotoxicity, especially in children, but it is unclear whether it can cause late cardiotoxicity (Gottdiener et al, 1981; Steinherz and Yahalom, 1993) . In 18 adults with haematological diseases (mean age 35 years) treated with high-dose cyclophosphamide (5.5-8 g m-2), only one patient (5.5%) developed a mild CHF with decrease of LVEF to 40% (Braverman et al, 1991) . For the CE combination, we have reported the results of a phase I study using 7 g m-2 cyclophosphamide and 2-2.5 g m-2 etoposide without radiotherapy. No acute cardiotoxicity was observed in six patients (Mulder et al, 1984) . Mitoxantrone given after anthracyclines in an ablative regimen in a cumulative dose of 100 mg m-2 may lead to 3% CHF (Shenkenberg and Von Hoff, 1986) . In the study of Bowers et al (1993) , 44 breast cancer patients were treated with escalating doses of mitoxantrone in combination with 900 mg m-2 thiotepa after pretreatment with 160-492 mg ni-2 doxorubicin. No acute cardiotoxicity was observed using 50 mg m-2 mitoxantrone in 13 patients whereas, after 60 mg m-2 mitoxantrone, CHF occurred in 4 out of 31 patients (13%). One patient developed acute pericarditis and four patients had a . 10% decline in LVEF, amounting to an overall incidence of acute cardiotoxicity of 29% (Bowers et al, 1993) . In the present study, we found that life-threatening cardiotoxicity is a rare complication and late subclinical cardiotoxicity was found in 4 of 27 evaluated patients at a median 2 years' follow-up, which occurred in all ablative regimens and was not restricted to a particular schedule. The estimated percentage of patients free of cardiac dysfunction, including the two clinical and four subclinical events, at 5 years is 94% (95% CI 88-100%) and at 7 years 78% (95% CI 61-95%). These results are hampered by a limited follow-up and a small number of events, although an increasing incidence of cardiac dysfunction at longer follow-up is suggested. Important is the recognition that the patients treated with intensive chemotherapy are, in general, young adults without a pre-existent cardiac history. Because of the curative intent of the intensive treatment, the evaluation of cardiotoxicity is of importance for the future quality of life of these patients. The risk of long-term cardiotoxicity is especially important in the adjuvant setting and is much more of a theoretical concern in the therapy of metastatic disease as, if these patients should live long enough to experience such late effects, this would be regarded as a victory for the treatment.
In conclusion, thus far, the low incidence of clinical and subclinical cardiotoxicity in adult breast cancer patients does not hamper the use of intensive chemotherapy combined with radiotherapy in patients who would otherwise have a poor chance of survival.
